3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sezary Syndrome
1
Sarcoma, Synovial
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Mycosis Fungoides
1
Liposarcoma, Myxoid
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Neoplasms
1
Interventions
Temozolomide
48
Bevacizumab
29
Carmustine
17
Erlotinib Hydrochloride
16
Radiotherapy
14
Irinotecan
14
Surgical Procedures, Operative
10
Sirolimus
10
Imatinib Mesylate
10
Carboplatin
10
Sorafenib
9
O(6)-benzylguanine
9
Filgrastim
9
Etoposide
8
temsirolimus
7
sargramostim
7
Radiosurgery
7
Radiation
7
Procarbazine
7
Magnetic Resonance Spectroscopy
7
Cyclophosphamide
7
aldesleukin
6
Topotecan
6
Thalidomide
6
Vorinostat
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Hydroxyurea
5
Gefitinib
5
Everolimus
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
interferon gamma-1b
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled